Four-Minute Heart Attack Risk Assessment: AccuLine Completes Clinical Trial in Israel

1 February, 2026

The company’s system demonstrated 94% sensitivity in detecting coronary artery disease and ruled out risk with 99% certainty—without radiation or invasive procedures

AccuLine announced on Thursday the successful completion of a multi-center clinical trial in Israel evaluating its CORA system for the early detection of coronary artery disease—the leading cause of heart attacks. According to the company, the test takes approximately four minutes, is designed to be performed in a clinic setting, and does not require catheterization, radiation, or contrast agents.

The clinical trial was conducted across seven medical centers in Israel, including Ichilov Medical Center, Poriya Medical Center, Assuta Tel Aviv, Shamir Medical Center, Wolfson Medical Center, Assuta Ashdod, and Hillel Yaffe Medical Center.

The study included 305 participants, with results benchmarked against coronary angiography, considered the gold standard for diagnosing coronary artery disease. According to the data, the CORA system achieved 94% sensitivity in identifying patients with significant coronary artery stenosis, alongside a negative predictive value (NPV) of 99% for ruling out the disease. The company notes that these results represent a substantial improvement over commonly used stress tests in community healthcare settings.

“Early and accurate diagnosis at the initial stages could save the lives of millions of people who are not diagnosed in time,” said Moshe Bar-El, AccuLine’s CEO and co-founder. “For the first time, we are providing primary care physicians with a tool that allows them, within minutes, to distinguish between patients who require further evaluation and those who are not at risk—while avoiding unnecessary and costly tests.”

No Radiation, Powered by AI

The CORA system is based on an artificial intelligence algorithm that simultaneously analyzes electrical signals from the heart, blood oxygen levels, respiratory rate, and the patient’s medical background. The output is an immediate report on the condition of the coronary arteries—without the need for invasive procedures or advanced imaging equipment.

Beyond its clinical implications, AccuLine also emphasizes the economic potential of the technology. Cardiology accounts for hundreds of billions of dollars in healthcare spending annually, and a solution capable of reducing expensive diagnostic tests and complex treatments following heart attacks could have a significant impact on healthcare systems and insurance providers.

Following the successful results of the Israeli trial, AccuLine is preparing for a large-scale clinical study in the United States. The trial will take place across 20 medical centers and include approximately 2,000 patients. It will be conducted in collaboration with Mayo Clinic and represents a key step toward FDA approval and the system’s entry into the U.S. and global markets.

AccuLine was founded in early 2022 and has raised approximately $5.5 million to date, led by eHealth Ventures with participation from Maccabi Healthcare Services. The funding includes grants from the Israel Innovation Authority and Google, as well as a strategic investment and collaboration with Mayo Clinic.

The company’s team includes CEO Moshe Bar-El, CTO Dr. Amit Raches, CBO Don Crawford, CMO Prof. Aharon Frimerman—head of the catheterization unit at Hillel Yaffe Medical Center—and CSO Prof. Shay Revzun from the University of Michigan. AccuLine currently employs seven people at its offices in Petah Tikva.

Share via Whatsapp

Posted in: News

Posted in tags: AccuLine

Other articles you might like

AIR and ST Engineering Unveil Cargo UAV for the European Market

Intel Cancels Manufacturing deal With Tower Semiconductor

InnovizSMART Security System Deployed at Critical Infrastructure Sites in Israel